Biotech Co.* |
Pharma Co. |
Product | Terms/Details (Date) |
Abraxis |
Pfizer Inc. |
Abraxis is buying Pfizer's Cruce Davila manufacturing facility in Puerto Rico |
They entered a definitive agreement on the deal, terms of which were not disclosed (4/25) |
Affymax Inc.* |
American Peptide Co. Inc. |
Deal for the manufacture of Affymax's Hematide |
The synthetic, peptide-based erythro- poiesis-stimulating agent is in Phase II trials; terms were not disclosed (4/5) |
BioviRx Inc.* |
IDT GmbH (Germany; unit of the Klocke Group) |
Deal under which IDT will manufacture the oral rotavirus vaccine RotaShield for BioviRx |
BioviRx plans to reintroduce the vaccine to the market after a re-analysis of data; it was approved in 1998 but taken off the market in 1999 (3/27) |
Chiron Corp (CHIR) |
Schering AG (Germany) |
Schering said it will exercise its option to buy or lease all assets used by Chiron in the manufacture of Betaseron |
The deal covering the interferon beta-1b product was subject to the closing of the acquisition of Chiron by Novartis AG; the price will be determined (2/24) |
Chromos |
AppTec Laboratory Services Inc. |
Deal for the scale-up and manufacture of Chromos' monoclonal antibody candidate CHR-1103 |
AppTec will manufacture product for pre- clinical and Phase I studies; the product is being developed for multiple sclerosis; terms were not disclosed (4/6) |
CytoGenix |
GE Healthcare |
GE will provide production reagents for use in the manufacture of vaccines and compounds by CytoGenix |
CytoGenix will be GE's exclusive customer for re-agents where the intended application is the manufacture of therapeutic compounds using CytoGenix's processes (3/23) |
Dendreon |
Diosynth Biotechnology (unit of NV Organon) |
Deal under which Diosynth will manufacture the recombinant antigen component of Dendreon's Provenge |
Provenge is a cellular immunotherapy product being studied for prostate cancer; the deal reflects a continuing collaboration between the companies (3/2) |
Dynogen |
Astellas Pharma Inc. (Japan) |
Astellas acquired Dynogen's North Carolina- based research facility |
The facility specializes in preclinical studies for genitourinary disorders; terms were not disclosed (3/1) |
Forbes |
Chusei Oil Co. Ltd. (Japan) |
Chusei purchased Forbes' interest in their 50-50 Phyto-Source LP sterol manufacturing joint venture |
Forbes gets a $25M payment; they also entered an agreement that will ensure Forbes a supply of Reducol and other wood sterols for five years (2/23) |
GNI Ltd.* |
Beijing Continent Pharmaceutical Co. Ltd. (China) |
GNI took a stake in BCP as part of a strategic alliance |
The deal gives GNI access to BCP's manufacturing facilities, sales force and sales distribution network (4/11) |
Interleukin |
Access Business Group International LLC (subsidiary of Alticor Inc.) |
An Alticor subsidiary got rights to market two genetic tests, one for heart health and one covering general nutrition |
The test will be marketed exclusively through Alticor subsidiary Quixtar, under Quixtar's Gensona brand (2/28) |
Martek |
F. Hoffmann- La Roche Ltd. (Switzerland) |
Martek will help Roche in the production of shikimic acid |
Shikimic acid is the starting material used to produce Roche's Tamiflu; terms were not disclosed (3/16) |
Nabi Bio- |
Sanofi Pasteur (France) |
Nabi will help in the manufacture of the rabies product Imogam Rabies-HT |
Nabi will fractionate human plasma used for the production of the immune globulin product; terms were not disclosed (4/26) |
Novavax Inc. |
PacificGMP LLC |
Deal to develop a commercial-scale production process for Novavax's pandemic influenza |
The deal centers on Novavax's H5N1 avian influenza vaccine, based on its virus-like particle technology (2/28) |
SciGen Ltd. |
Shreya Group (India) |
Deal under which SciGen would acquire Shreya's manufacturing facility in India |
Shreya previously was SciGen's contract manufacturer for biotechnology-derived products; terms were not disclosed (4/5) |
Seattle |
Laureate Pharma Inc. |
Deal for the manufacture of Seattle Genetics' SGN-33 and SGN-70 humanized monoclonal antibody product candidates |
Laureate Pharma will perform scale-up and manufacturing of clinical trial materials for both programs; terms were not disclosed (4/25) |
Serologicals |
Novo Nordisk |
Celliance Corp. got rights to distribute Novo's recombinant human insulin in the cell culture market |
Celliance is a Serologicals subsidiary; terms of the expanded four-year supply agreement were not disclosed (3/16) |
Sinovac Biotech |
LG Life Sciences Ltd. (South Korea) |
Sinovac will act as exclusive distributor for LGLS' hepatitis B vaccine in China |
Terms of the deal were not disclosed (3/13) |
Notes: | |||
# The information in the chart does not cover agricultural agreements or those between biotech companies. | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
AMEX = American Stock Exchange; ASX = Australian Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; TSE = Toronto Stock Exchange. | |||
To read more on related topics, click on one of the words below.